Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Gynecol Oncol. 2010 Sep 17;119(3):462–468. doi: 10.1016/j.ygyno.2010.08.028

Table 5.

Multivariate Cox proportional hazards models for survival among non-mucinous invasive post-op study cases.

Model 1 Model 2

HR (95% CI) p HR (95% CI) p
CA125 35–1750 (vs. <35) 2.64 (1.15, 6.10) 0.02 1.37 (0.57, 3.29) 0.48
CA125 >1750 (vs. <35) 4.33 (1.81, 10.4) 0.001 1.92 (0.76, 4.85) 0.17
p-trend for CA125 categories above* <0.0001 0.04
Age (years) 1.04 (0.88, 1.23) 0.61 1.00 (0.84, 1.18) 0.97
Age (years), squared 1.00 (1.00, 1.00) 0.74 1.00 (1.00, 1.00) 0.79
Jewish 1.02 (0.66, 1.58) 0.94 0.92 (0.59, 1.44) 0.73
BMI (quintiles) 1.01 (0.97, 1.04) 0.80 1.01 (0.97, 1.04) 0.72
Parity (continuous) 1.04 (0.94, 1.15) 0.49 1.00 (0.90, 1.11) 0.99
Yeast infections 1.39 (0.19, 10.4) 0.75 1.17 (0.16, 8.68) 0.88
Appendectomy 0.81 (0.54, 1.24) 0.33 0.75 (0.49, 1.14) 0.18
Colitis 2.09 (0.75, 5.78) 0.16 2.53 (0.91, 7.04) 0.07
History of breast cancer 1.03 (0.59, 1.79) 0.93 1.06 (0.61, 1.86) 0.83
Endometrioid/clear cell (vs. serous) 0.18 (0.09, 0.37) <0.0001 0.35 (0.16, 0.76) 0.008
Mixed/other/Undiff. (vs. serous) 0.52 (0.32, 0.83) 0.006 0.54 (0.33, 0.86) 0.01
Stage 3–4 (vs. 1–2) 2.57 (1.48, 4.47) 0.0008
Ascites (any vs. none) 1.99 (1.32, 3.01) 0.001
*

The test for trend evaluates whether the association between categories of CA125 and survival increases or decreases across CA125 categories in a significantly linear pattern.